Table 4.

Baseline neutrophil count, lymphocyte count, and neutrophil-to-lymphocyte ratio as predictors of worsening SSc-ILD in SLS II

	Neutrophil		Lymphocyte		NLR*
Characteristic	β [95% CI]	P-value	β [95% CI]	P-value	β [95% CI]	P-value
Baseline count or ratio	−1.14 [−1.18, −1.10]	0.033	1.34 [1.31, 1.38]	0.018	−1.16 [−1.19, −1.13]	<0.001
Baseline FVC%	0.91 [0.91, 0.91]	<0.001	0.90 [0.90, 0.90]	<0.001	0.90 [0.90, 0.91]	<0.001
Time variable	0.17 [0.16, 0.17]	0.024	0.17 [0.16, 0.18]	0.028	0.17 [0.17, 0.18]	0.014
Treatment arm†	0.99 [0.94, 1.04]	0.112	0.94 [0.89, 0.99]	0.139	1.04 [1.00, 1.08]	0.074

Analysis by joint model (14)

^*Neutrophil-to-lymphocyte ratio

^†Mycophenolate compared to cyclophosphamide treatment groups